舌下免疫治疗过敏性鼻炎可升高凝血酶激活纤溶抑制物
该回顾性队列结合实验室研究检测了日本柳杉花粉过敏患者接受舌下免疫治疗(SLIT)前后血清TAFI、C3a、C5a水平及其与症状-药物评分的关系。结果显示SLIT后血清TAFI显著升高、C3a随时间显著下降,TAFI与C3a及症状-药物评分呈显著负相关;体外实验提示TAFI可抑制肥大细胞脱颗粒及成纤维细胞CCL11、CCL5表达。
要点
- SLIT后血清TAFI显著升高,C3a随时间显著下降。
- TAFI与C3a及症状-药物评分呈显著负相关。
- TAFI可抑制肥大细胞脱颗粒及成纤维细胞趋化因子表达。
核心结论
- 舌下免疫治疗可诱导血清TAFI升高,TAFI可能通过灭活C3a、抑制肥大细胞脱颗粒及成纤维细胞趋化因子表达在过敏性鼻炎发病中发挥保护作用。
研究设计与样本
- 回顾性队列研究联合实验室研究,采集日本柳杉花粉过敏患者SLIT治疗前、治疗中及治疗后的血清。
主要发现
- 血清TAFI水平对SLIT反应显著升高。
- 血清C3a水平随时间显著下降。
- 血清TAFI与C3a及症状-药物评分之间呈显著负相关。
- 体外实验中TAFI抑制肥大细胞脱颗粒。
- 体外实验中TAFI抑制培养成纤维细胞CCL11和CCL5表达。
关键数值与推荐
- 采用酶联免疫吸附试验(ELISA)测定血清免疫反应性TAFI、C3a和C5a水平。
- 评估上述指标对症状-药物评分的相对影响。
临床怎么用
- TAFI可能作为评估SLIT治疗效果的候选生物标志物。
- TAFI升高与症状-药物评分负相关,提示其或可反映治疗反应。
局限性
- 证据等级为4级。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES/HYPOTHESIS: The objective of this study was to determine the role of thrombin-activatable fibrinolysis inhibitor (TAFI) as a candidate biomarker for therapeutic efficacy of sublingual immunotherapy (SLIT) and to identify the role of TAFI in the pathogenesis of allergic rhinitis (AR). STUDY DESIGN: Retrospective cohort study and laboratory study. METHODS: Serum was collected from patients with allergies to Japanese cedar pollen before, during, and after treatment with SLIT. We measured the levels of immunoreactive TAFI, C3a, and C5a in serum by enzyme-linked immunosorbent assay (ELISA) and assessed their relative impact on a combined symptom-medication score. We also examined the impact of TAFI on mast cells and fibroblasts in experiments performed in vitro. RESULTS: Serum levels of TAFI increased significantly in response to SLIT. By contrast, serum C3a levels decreased significantly over time; we observed a significant negative correlation between serum levels of TAFI versus C3a and symptom-medication score. Mast cell degranulation was inhibited in response to TAFI, as it was the expression of both CCL11 and CCL5 in cultured fibroblasts. CONCLUSIONS: High serum levels of TAFI may be induced by SLIT. TAFI may play a critical protective role in pathogenesis of AR by inactivating C3a and by inhibiting mast cell degranulation and chemokines expression in fibroblasts. LEVEL OF EVIDENCE: 4 Laryngoscope, 131:2413-2420, 2021.
引用
- Yoshida K, Takabayashi T, Imoto Y, et al. Increased Thrombin-Activatable Fibrinolysis Inhibitor in Response to Sublingual Immunotherapy for Allergic Rhinitis. Laryngoscope. 2021. PMID: 33844301. doi:10.1002/lary.29563
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。